Loading...

MedXY AI/MedXY News/Tag: immunotherapy

MedXY News

EnglishTag

immunotherapy

146 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

Updated ASTRUM-005 results confirm serplulimab’s significant survival benefit in extensive-stage small-cell lung cancer (15.8 vs. 11.1 months). Exploratory analyses identify a 15-protein signature and RB1/Notch mutations as potential predic

Section: newsJan 14, 2026

$Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors$

Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors

A Phase 1b study demonstrates that combining SBRT with the bispecific antibody cadonilimab (PD-1/CTLA-4) is safe and effective for refractory solid tumors, yielding a 23.8% response rate and 7.2-month median PFS in patients who failed multi

Section: newsJan 14, 2026

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and managea

Section: GastroenterologyJan 14, 2026

Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial

Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial

The Phase III ALBAN trial found that adding atezolizumab to BCG therapy did not improve event-free survival in BCG-naive high-risk non-muscle-invasive bladder cancer, highlighting the complexity of immune checkpoint inhibitor synergy in thi

Section: newsJan 14, 2026

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interac

Section: Diabetes & EndocrinologyJan 14, 2026

Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC

Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC

The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m

Section: newsJan 14, 2026

Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer

Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer

Researchers have discovered that Zhenqi Fuzheng Granule enhances PD-1 antibody efficacy in colorectal cancer by modulating the gut microbiota-SCFA-GPR109A axis, effectively suppressing tumor glycolysis and reversing immune exhaustion within

Section: GastroenterologyJan 13, 2026

$Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL$

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

The ZUMA-6 trial investigated combining axicabtagene ciloleucel with atezolizumab for refractory DLBCL. While the combination was safe with a 54% complete response rate, efficacy and CAR T-cell expansion were comparable to monotherapy, high

Section: newsJan 13, 2026

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino

Section: newsJan 13, 2026

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial

The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profil

Section: newsJan 13, 2026

Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial

Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial

A Phase Ib study of the IL-2 variant immunocytokine cergutuzumab amunaleukin plus atezolizumab demonstrates manageable safety and robust peripheral immune activation but modest clinical activity in CEA-positive advanced solid tumors.

Section: newsJan 13, 2026

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial

A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highl

Section: GastroenterologyJan 13, 2026

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight

Section: GastroenterologyJan 13, 2026

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study

A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and g

Section: GastroenterologyJan 13, 2026

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS

Section: newsJan 13, 2026

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p

Section: newsJan 13, 2026

Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma

Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma

Recent clinical trials reveal that LBL-007, a novel anti-LAG-3 antibody, significantly enhances treatment outcomes for advanced nasopharyngeal carcinoma when combined with PD-1 inhibitors, marking a potential shift in the standard of care f

Section: newsJan 12, 2026

Precision Management of KRAS G12V-Mutated NSCLC: Molecular Insights and Therapeutic Strategies

Precision Management of KRAS G12V-Mutated NSCLC: Molecular Insights and Therapeutic Strategies

This article synthesizes recent findings on the KRAS G12V mutation in non-small cell lung cancer, highlighting its unique molecular profile, strong association with smoking, and superior response to immunotherapy compared to traditional che

Section: newsJan 12, 2026

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma

Section: newsJan 12, 2026

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.

Section: GastroenterologyJan 12, 2026

Prev 1 2 3 4 5 8 Next